Neuroone Medical Technologies (NMTC) Net Margin (2011 - 2026)

Neuroone Medical Technologies has disclosed Net Margin across 12 years of filings, most recently posting 127.92% for Q1 2026.

• Quarterly Net Margin rose 3583.0% year-over-year to 127.92% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 75.5% (up 3916.0% YoY) and the FY2025 annual result came in at 39.63%, up 31711.0% from the prior year.
• Net Margin eased to 127.92% in Q1 2026, from 49.71% in the prior quarter.
• Across five years, Net Margin topped out at 54.53% in Q4 2024 and bottomed at 8610.96% in Q2 2022.
• The 5-year median for Net Margin is 342.14% (2023), against an average of 1456.4%.
• Year-over-year, Net Margin plunged 124961 bps in 2022 and surged 806028 bps in 2023.
• Neuroone Medical Technologies' Net Margin stood at 1512.29% in 2022, then jumped by 77 bps to 342.14% in 2023, then soared by 116 bps to 54.53% in 2024, then sank by 191 bps to 49.71% in 2025, then sank by 157 bps to 127.92% in 2026.
• According to Business Quant data, Net Margin over the past three periods registered 127.92%, 49.71%, and 59.08% for Q1 2026, Q4 2025, and Q3 2025 respectively.